Gottfried E Konecny

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint [Retrospective analysis of dose intensity of epirubicin in breast cancer]
    G Konecny
    Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe im Klinikum Grosshadern der Ludwig Maximilians Universität München, Deutschland
    Gynakol Geburtshilfliche Rundsch 40:145-52. 2000
  2. ncbi request reprint Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Cancer Res 66:1630-9. 2006
  3. ncbi request reprint Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression
    Gottfried E Konecny
    University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1678, USA
    Oncology (Williston Park) 18:32-6. 2004
  4. ncbi request reprint HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
    G Konecny
    Department of Medicine, UCLA School of Medicine, 90095 1678, USA
    Breast Cancer Res Treat 69:53-63. 2001
  5. ncbi request reprint Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples
    G Konecny
    Department of Medicine, University of California, Los Angeles School of Medicine, 90095 1678, USA
    Breast Cancer Res Treat 67:223-33. 2001
  6. ncbi request reprint Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer
    G Konecny
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 7:1743-9. 2001
  7. ncbi request reprint Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
    G Konecny
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1678, USA
    Clin Cancer Res 7:2448-57. 2001
  8. ncbi request reprint Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Mark D Pegram
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:739-49. 2004
  9. ncbi request reprint Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004
  10. doi request reprint Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E Konecny
    UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
    Breast Cancer Res Treat 120:481-9. 2010

Collaborators

Detail Information

Publications19

  1. ncbi request reprint [Retrospective analysis of dose intensity of epirubicin in breast cancer]
    G Konecny
    Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe im Klinikum Grosshadern der Ludwig Maximilians Universität München, Deutschland
    Gynakol Geburtshilfliche Rundsch 40:145-52. 2000
    ..We retrospectively determined the administered dose intensity and the relative toxicity and efficacy of an epirubicin-containing regimen in patients with primary or metastatic breast cancer...
  2. ncbi request reprint Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Cancer Res 66:1630-9. 2006
    ..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab...
  3. ncbi request reprint Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression
    Gottfried E Konecny
    University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1678, USA
    Oncology (Williston Park) 18:32-6. 2004
    ..These findings indicate that trastuzumab plus gemcitabine and trastuzumab plus gemcitabine plus cisplatin or carboplatin are rational combinations to evaluate in clinical trials...
  4. ncbi request reprint HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
    G Konecny
    Department of Medicine, UCLA School of Medicine, 90095 1678, USA
    Breast Cancer Res Treat 69:53-63. 2001
    ..In contrast, tumors with strong HER-2/neu overexpression demonstrated increased dose-dependent in vitro sensitivity to both the FEC and CMF regimens...
  5. ncbi request reprint Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples
    G Konecny
    Department of Medicine, University of California, Los Angeles School of Medicine, 90095 1678, USA
    Breast Cancer Res Treat 67:223-33. 2001
    ....
  6. ncbi request reprint Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer
    G Konecny
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 7:1743-9. 2001
    ..The current study tests the hypothesis that elevated expression of uPA and PAI-1 is associated with prognosis and disease progression...
  7. ncbi request reprint Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
    G Konecny
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1678, USA
    Clin Cancer Res 7:2448-57. 2001
    ....
  8. ncbi request reprint Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Mark D Pegram
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:739-49. 2004
    ..We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer...
  9. ncbi request reprint Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004
    ....
  10. doi request reprint Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E Konecny
    UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
    Breast Cancer Res Treat 120:481-9. 2010
    ..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status...
  11. doi request reprint Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:632-42. 2013
    ..Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection...
  12. pmc Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer
    Maike Ihnen
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:1002-15. 2013
    ..These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer...
  13. doi request reprint Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 17:1591-602. 2011
    ..PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer...
  14. pmc Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
    Chintda Santiskulvong
    Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 1740, USA
    Clin Cancer Res 17:2373-84. 2011
    ..This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy...
  15. ncbi request reprint Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
    Gottfried E Konecny
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 10:1706-16. 2004
    ..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome...
  16. doi request reprint Emerging strategies for the dual inhibition of HER2-positive breast cancer
    Gottfried E Konecny
    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90404 2429, USA
    Curr Opin Obstet Gynecol 25:55-65. 2013
    ..To review the recently published trials to help us refine and optimize the use of approved HER2-targeted agents (trastuzumab and lapatinib) and highlight future combination strategies for the treatment of HER2-positive breast cancer...
  17. pmc Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
    Marlena S Fejzo
    Division of Hematology Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Int J Mol Sci 14:3094-109. 2013
    ..Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer...
  18. pmc Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer
    Chen Wang
    Authors Affiliations Departments of Health Sciences Research, Medical Oncology, Obstetrics and Gynecology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles Department of Research, Illumina, San Diego, California Departments of Cancer Biology and Biostatistics, University of Kansas Medical Center, Kansas City, Kansas and Vaccine and Gene Therapy Institute of Florida, Port St Lucie, Florida
    Cancer Res 74:3084-91. 2014
    ..Collectively, these results suggest that an epigenetically mediated immune response is a predictor of recurrence and, possibly, treatment response for HGS EOC...
  19. ncbi request reprint Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
    Gottfried E Konecny
    J Natl Cancer Inst 95:1813-5. 2003